Skip to main content

ORTHOFIX International N V Value Stock - Dividend - Research Selection

Orthofix international n v

ISIN: US68752M1080 , WKN: A2NB0X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

2026-07-21
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.

Monday's session: gap up and gap down stocks

2026-07-06
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Reported July 2, 2026: Orthofix Medical Says Medicare Will Restore Pre-May 18 Reimbursement Rates For Bone Growth Stimulators After CMS Reversal

2026-07-06
On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. Following that order, the Centers for

Terawulf, Ceva, Western Digital And Other Big Stocks Moving Higher On Monday

2026-07-06
Stocks mixed, Dow falls 100 points. Terawulf Inc (NASDAQ: WULF) rises after lease deal. Other big gainers: OFIX, AXTI, SHAZ, IREN, CEVA, IMOS, CRDO, HUT, BFLY, CHRN, BE, ALAB, SIMO.

Stay updated with the stocks that are on the move in today's after-hours session.

2026-07-02
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

12 Health Care Stocks Moving In Thursday's After-Market Session

2026-07-02
Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals (NASDAQ:UPC)

Orthofix Medical (OFIX) Stock Sees Split Analyst Revisions After CMS Reimbursement Reset

2026-06-18
The latest analyst update on Orthofix Medical keeps the model fair value steady at US$15.0 per share, signaling no reset to the core price target despite refreshed assumptions. This stable fair value sits against a backdrop of mixed analyst commentary, with some focusing on the reset in reimbursement expectations for non invasive bone growth stimulators and others stressing the earnings headwind from the new CMS framework. As you read on, you will see how these shifting views shape the...

Alpha Buying: Wall Street Gave Up. Management Didn't.

2026-06-18

Orthofix Medical Inc. (OFIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

2026-06-08
Orthofix Medical Inc. (OFIX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 8:40 AM EDTCompany ParticipantsMassimo Calafiore -...

How The Orthofix Medical (OFIX) Narrative Is Resetting After CMS Cuts And Guidance Changes

2026-06-04
Orthofix Medical is back in focus after a recent reset of its fair value estimate, with the price target moving from US$17.25 to US$15.00, a cut of about 13%. That change lines up with a Street narrative that mixes caution and optimism as analysts weigh the impact of CMS reimbursement updates and the company’s revised long term outlook. Read on to see how different analysts are framing this reset and how you can follow the story as it continues to evolve. Wall Street's queuing for one rocket...